A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia

[摘要] Chronic lymphocytic leukemia (CLL) was projected to cause 4320deaths in 2021 in the US [1]. Chemo-immunotherapy regimens arecommonly associated with unfavorable adverse events (AEs) [2, 3]. Targeted therapies such as the Bruton’s tyrosine kinase (BTK) inhibitoribrutinib are better tolerated and have become standard of care forCLL. Ibrutinib causes egress of CLL cells from their stromal niche leading to peripheral lymphocytosis [4]. While initially successful in treatment of naïve, relapsed/refractory, and high risk CLL (deletion 17p),most high risk patients experienced disease progression, indicating aneed to improve BTK-targeted therapy regimens.